# Karyopharm to Participate at Upcoming Investor Conferences
Canonical URL: https://biopharmsignal.com/news/KPTI/karyopharm-to-participate-at-upcoming-investor-conferences
Ticker: KPTI
Company: Karyopharm Therapeutics
Source: Karyopharm Therapeutics
Published: 2026-05-12 11:30 EST
Original Source URL: https://investors.karyopharm.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-01 20:05 EST — [Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-cc27221e) — Source: Karyopharm Therapeutics
- 2026-06-03 20:15 EST — [Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026](https://biopharmsignal.com/news/KPTI/karyopharm-to-participate-in-webcast-featuring-endometrial-cancer-key-opinion-leader-on-june-8-2026) — Source: Karyopharm Therapeutics
- 2026-06-02 14:02 EST — [Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026](https://biopharmsignal.com/news/KPTI/karyopharm-s-phase-3-sentry-trial-of-selinexor-plus-ruxolitinib-in-myelofibrosis-selected-for-late-breaking-oral-presentation-at-eha-2026) — Source: Karyopharm Therapeutics
- 2026-06-02 12:59 EST — [Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology](https://biopharmsignal.com/news/KPTI/karyopharm-to-present-results-from-phase-3-sentry-trial-of-selinexor-plus-ruxolitinib-in-myelofibrosis-in-late-breaking-oral-presentation-at-asco-2026-with-simultaneous-publication-in-the-journal-of-clinical-oncology) — Source: Karyopharm Therapeutics
- 2026-06-01 20:05 EST — [Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4) — Source: Karyopharm Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)